Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes
Background: Abiraterone acetate is an effective treatment for metastatic castrate-resistant prostate cancer (mCRPC), but evolution of resistance inevitably leads to progression. We present a pilot study in which abiraterone dosing is guided by evolution-informed mathematical models to delay onset of...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
eLife Sciences Publications Ltd
2022-06-01
|
| Serie: | eLife |
| Soggetti: | |
| Accesso online: | https://elifesciences.org/articles/76284 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|